


DELOS FORMULATION TECHNOLOGY


Development and Manufacturing
of **nanomedicines** and tailored
drug delivery systems using
patented **nanoparticles**



NANOMOL
TECHNOLOGIES

Adding Value to your molecules

**INNOVATE
WITH DELOS
PARTICLE
TECHNOLOGY
AND ACHIEVE...**





ENHANCED DRUG PRODUCTS

- Reformulate drug candidates, small molecules or biologics, with poor solubility, bioavailability or stability.
- Obtain **novel, tailored drug delivery systems**:
 - Selective Targeting.
 - Overcome cell barriers.



EFFICIENT PRODUCTION

- Single step, **green & robust manufacturing** procedure.
- Reduce organic solvents and carbon footprint.
- Reduce dosing, save costly APIs.



COMMERCIAL OPPORTUNITIES

- **Unlock pharmaceutical development** of drug candidates.
- Reformulate as **Value-Added Medicines**.
- File **patents** for new formulations or solid forms.
- Extend **product life cycle**.

OUR DELOS TECHNOLOGY

HIGH CONTROL ON PARTICLE PROPERTIES



Delos

- **Green, sustainable plug-and-play platform**, based on compressed CO₂ as cosolvent.
- Tested with success for **+50 actives**.



small molecules



proteins



peptides



DNA
RNA


- **Scale-up demonstrated** from lab (ml) to pilot plant (L).
- **GMP pilot manufacturing**

HOMOGENEOUS

Granted procedure patents.
New IP is possible for specific APIs
and indications

Advanced Liposomal & unilamellar vesicles


- Very stable **nanovesicles** (>3 years)
- **Bioactive conjugates**
- **Multifunctional**, tailored drug



POWDERED SOLID PARTICLES

Homogeneous **microstructure**.
High control of **size, morphology, solid form, purity...**

- **Pure APIs** (polymorphs, thermolabile, poorly water soluble).
- **API-polymer composites** (stable amorphs).




COLLOIDAL SYSTEMS

non-liposomal small
(novel class)

at RT)

nanocarriers.



DELOS NANOCARRIERS

WE REFORMULATE YOUR ACTIVES IN NOVEL NANOVESICLE BASED FORMULATIONS

- **Tunable particle size** from 70 to 200 nm.
- **Active Loading** up to 40% w/w.
- Extremely **high colloidal stability** (>3 years).
- Stabilization of **lipophilic molecules in aqueous media**.
- **Efficient and versatile integration of several drug modalities:**



small molecules



proteins




peptides



DNA
RNA

- **Combination of hydrophilic/ lipophilic actives.**
- **Multifunctional** systems (e.g. in-built antimicrobial activity, or targeting functionalization).
- Robust systems than can be **nebulized, lyophilized or integrated in water based formulations** (e.g. hydrogels).
- Enabling technology for **topical, intravenous, subcutaneous and inhalation administration routes**. Currently developing oral routes.





OUR TEAM

WHY CHOOSE US

Nanomol Technologies provides **expert and proprietary nanoparticle formulation technology from early preclinical development up to the clinical phase** for the pharma and biotech industry. Our qualified team holds a vast knowledge in particle engineering and nanomedicine development

ABOUT US

We were born in 2010 with the purpose of **unlocking pharmaceutical R&D, by providing advanced solutions and technologies** for the development of next generation medicines.



Santi Sala
CEO



Alba Córdoba
Business Development &
Tech Transfer Director



Lidia Ferrer
R&D Director



Mòdul de recerca B (UAB Campus)
08193 Bellaterra / Cerdanyola del Vallès
(Barcelona) Spain



acordoba@nanomol-tech.com



www.nanomol-tech.com



NANOMOL
TECHNOLOGIES